Ferreira Clara, Azevedo Alexandra, Nogueira Miguel, Torres Tiago
Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.
Drugs Context. 2020 Mar 9;9. doi: 10.7573/dic.2019-11-6. eCollection 2020.
The onset of psoriasis collides with women's reproductive timeframe, and pregnancy brings challenges to its treatment. Indeed, the health of both mother and foetus must be considered. When choosing to treat pregnant women affected by psoriasis with pharmacological therapy, it is important to be aware of all possible options and their repercussions. Although there are several pharmacological therapies available, pregnancy brings ethical concerns and any pharmacological approach must be well thought out. The data available in humans are limited, and further investigation on this matter is needed. Within biological therapies, certolizumab pegol has recently been identified as a promising approach during pregnancy because it has been shown to have no late active placental transfer and no clear signs of foetal harm. This article aims to review the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.
银屑病的发病与女性的生育期相冲突，而怀孕给其治疗带来了挑战。确实，必须考虑母亲和胎儿双方的健康。当选择用药物疗法治疗患银屑病的孕妇时，了解所有可能的选择及其影响非常重要。尽管有几种可用的药物疗法，但怀孕带来了伦理问题，任何药物治疗方法都必须经过深思熟虑。人类可用的数据有限，对此问题需要进一步研究。在生物疗法中，赛妥珠单抗最近被确定为孕期一种有前景的方法，因为已证明它不会发生胎盘晚期活性转移，也没有明显的胎儿伤害迹象。本文旨在综述孕期银屑病的影响、根据现有治疗手段在此期间如何进行药物治疗，以及治疗选择对母亲和胎儿可能产生的影响。
